Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2026)

Tarsus Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $100.3 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 60.74% year-over-year to $100.3 million in Q1 2026; TTM through Mar 2026 was $100.3 million, a 60.74% increase from a year earlier, with the FY2025 full-year figure at $85.1 million, up 81.9% from the prior year.
• Receivables - Net improved to $100.3 million in Q1 2026 per TARS's latest filing, from $85.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $100.3 million in Q1 2026 and bottomed at $17000.0 in Q1 2022.
• The 5-year median for Receivables - Net is $29.5 million (2024), against an average of $35.9 million.
• Across the five-year window, Receivables - Net slumped 99.93% in 2022 and jumped 31441.18% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $17000.0 in 2022, then jumped by 97670.59% to $16.6 million in 2023, then surged by 181.33% to $46.8 million in 2024, then surged by 81.9% to $85.1 million in 2025, then gained by 17.97% to $100.3 million in 2026.
• Per Business Quant, the three latest TARS Receivables - Net figures stand at $100.3 million (Q1 2026), $85.1 million (Q4 2025), and $72.6 million (Q3 2025).